glp 1 for diabetes type 2 Oral Semaglutide Shows Promise in Adolescents with GLP 1 RAs Real World

Immunomodulatory effects of anti-diabetic therapies: Cytokine and chemokine modulation

Cao Y, Hlscher C, Hu MM, Wang T, Zhao F, Bai Y, et al

( Supplementary Figure 1A )

While published science is still slow to confirm the microbial mechanisms of GLP-1 induced constipation and the long-term impact, what we are finding in our clients is that over the long haul, if motility is not addressed, these shifts may become entrenched

Danuglipron, developed by Pfizer, showed 813% placebo-adjusted weight loss in Phase IIb studies, though high discontinuation rates highlight ongoing challenges with GI tolerability and formulation [87, 88]

[DOI] [PMC free article] [PubMed] [Google Scholar] 3.GLP-1 receptor agonists in the treatment of type 2 diabetes - state-of-the-art